tiprankstipranks
Trending News
More News >
Integrum AB Class B (SE:INTEG.B)
:INTEG.B

Integrum AB Class B (INTEG.B) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Integrum AB Class B

(Frankfurt:INTEG.B)

Rating:53Neutral
Price Target:
kr22.00
▲(8.91%Upside)
The stock's score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. Despite strong technical indicators suggesting bullish momentum, valuation concerns due to a negative P/E ratio weigh heavily. The absence of earnings call and corporate event data limits additional insights.

Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)

Integrum AB Class B Business Overview & Revenue Model

Company DescriptionIntegrum AB Class B (INTEG.B) is a Swedish company specializing in developing and marketing innovative solutions for orthopedic and reconstructive surgery, focused primarily on osseointegration technology. The company is renowned for its OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees) Implant System, which is designed to improve the quality of life for amputees by providing a direct connection between the prosthesis and the bone, enhancing mobility and comfort.
How the Company Makes MoneyIntegrum AB generates revenue primarily through the sale of its OPRA Implant System and related services. The company earns money by selling these advanced prosthetic solutions to healthcare providers and directly to patients globally. Additionally, Integrum engages in partnerships with medical institutions for research and development, which may also contribute to its revenue. The company leverages its expertise in osseointegration technology to expand its market presence and drive sales growth in the orthopedic and reconstructive surgery sectors.

Integrum AB Class B Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
90.01M104.12M74.27M55.72M43.09M26.75M
Gross Profit
54.83M91.26M60.84M46.56M34.89M21.37M
EBIT
-32.49M6.51M-19.70M1.04M-1.85M-15.68M
EBITDA
-22.34M8.76M-20.24M2.60M-1.59M-14.98M
Net Income Common Stockholders
-19.55M4.03M-16.18M21.27M-2.14M-15.69M
Balance SheetCash, Cash Equivalents and Short-Term Investments
14.65M16.90M41.92M75.34M7.66M13.06M
Total Assets
180.29M164.86M165.17M180.44M37.21M32.20M
Total Debt
5.25M6.42M7.92M580.89K485.92K723.80K
Net Debt
-9.40M-10.48M-34.01M-74.76M-7.17M-12.34M
Total Liabilities
17.69M22.07M21.64M20.70M12.91M8.47M
Stockholders Equity
162.60M142.79M143.53M159.74M24.29M23.73M
Cash FlowFree Cash Flow
-58.94M-24.37M-36.50M-49.55M-7.47M-19.06M
Operating Cash Flow
-44.88M-12.74M-25.10M-20.28M-5.76M-18.72M
Investing Cash Flow
-14.07M-11.63M-11.40M-29.27M-1.71M-343.68K
Financing Cash Flow
45.23M-648.54K3.08M117.23M2.06M21.51M

Integrum AB Class B Technical Analysis

Technical Analysis Sentiment
Positive
Last Price20.20
Price Trends
50DMA
15.85
Positive
100DMA
16.33
Positive
200DMA
20.93
Negative
Market Momentum
MACD
1.25
Negative
RSI
64.89
Neutral
STOCH
79.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 20.2 is above the 20-day moving average (MA) of 17.50, above the 50-day MA of 15.85, and below the 200-day MA of 20.93, indicating a neutral trend. The MACD of 1.25 indicates Negative momentum. The RSI at 64.89 is Neutral, neither overbought nor oversold. The STOCH value of 79.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.

Integrum AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
53
Neutral
kr430.95M-19.17%-12.50%-783.92%
50
Neutral
kr395.29M-33.54%72.05%33.68%
49
Neutral
kr531.83M-17.16%17.75%18.05%
47
Neutral
€594.56M-48.55%-2.22%-295.24%
46
Neutral
kr255.30M-88.97%-0.61%54.19%
43
Neutral
kr311.20M-159.24%-22.50%76.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:INTEG.B
Integrum AB Class B
20.05
-38.75
-65.90%
SE:ACARIX
Acarix AB
0.24
-0.07
-22.37%
SE:DOXA
Doxa AB
0.46
-0.82
-64.19%
SE:MNTC
Mentice AB
21.20
-5.80
-21.48%
SE:QLINEA
Q-linea AB
0.05
-0.34
-88.37%
SE:BRAIN
BrainCool AB
1.60
-0.90
-35.87%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.